27. EMPLOYEE BENEFITS EXPENSE

	For the Current Year ended 31.03.2015 ₹ in million	For the Previous Year ended 31.03.2014 ₹ in million
(Refer note 52)		
Salaries and Wages	14,144.7	12,322.5
Contribution to Provident and Other Funds	1,394.7	1,074.3
Retirement Benefits Expense [Refer note 39 (ii)]	211.5	137.2
Expenses on Employees Stock Options / Stock Appreciation Rights (Refer notes 37 & 38)	676.8	211.0
Staff Welfare Expenses	1,045.7	901.5
Total	17,473.4	14,646.5
Above includes Share of Joint Venture - jointly controlled entity	17.4	-

28. FINANCE COSTS

Interest on Borrowings	55.9	85.1
Other Borrowing Costs (includes bank charges, etc.)	42.2	167.5
Interest on Income Tax	-	13.9
Total	98.1	266.5

29. OTHER EXPENSES

Processing Charges	1,154.5	1,204.9
Stores and Spares Consumed	3,646.5	2,787.3
Repairs and Maintenance:		
- Buildings	314.8	237.4
- Plant and Machinery	753.0	702.4
- Others	953.1	722.1
Rent	360.7	333.1
Rates and Taxes	1,092.0	776.3
[Net of provision of earlier year adjusted ₹ 5.0 million (previous year ₹ nil)]		
Insurance	421.8	401.9
Power and Fuel	3,628.1	3,342.9
Contract Labour Charges	1,055.6	848.1
Excise Duty (net) (Refer note 49)	137.2	163.9
Selling and Promotion Expenses	5,654.9	5,057.1
Commission, Brokerage and Discount	1,234.7	1,230.9
[Including cash discount of ₹ 8.4 million (previous year ₹ 7.3 million)]		
Freight and Forwarding	1,465.2	1,464.6
Lease Rent and Hire Charges [Refer note 36(a)]	725.4	638.9
Postage and Telephone Expenses	334.3	327.1
Travelling and Conveyance	1,948.0	1,722.2
Legal and Professional Charges	3,115.0	3,841.8
[Net of recoveries of ₹ 330.2 million (previous year ₹ 79.3 million)]		
Donations (Refer note 52)	173.8	230.0
Clinical and Analytical Charges	1,682.0	1,311.0
Loss on sale / write-off of Fixed Assets (net)	43.1	119.4
Bad Trade Receivables / Advances / Deposits written off	54.3	8.9
[Net of provision of earlier years adjusted ₹ 33.4 million (previous year ₹ nil)]		
Impairment of Assets	-	429.0
Provision for Doubtful Trade Receivables / Advances / Deposits	1.8	273.7
Excess of carrying cost over fair value of Current Investments	2.5	-
Directors Sitting Fees	2.1	2.7
Exchange Rate Difference on Translation (net)	1,237.1	482.1
Miscellaneous Expenses	1,268.9	1,357.8
	32,460.4	30,017.5
Above includes Share of Joint Venture - jointly controlled entity	74.1	-

30. The Consolidated Financial Statements present the consolidated accounts of Lupin Limited ("the Company") and its following subsidiaries ("the Group ") and its jointly controlled entity:

Name of Subsidiaries / Jointly controlled entity	Country of Incorporation	Proportion of Ownership Interest	
		As at 31.03.2015	As at 31.03.2014
Lupin Pharmaceuticals, Inc.	USA	100%@	100%@
Kyowa Pharmaceutical Industry Co., Limited	Japan	100%+	100%+
Kyowa CritiCare Co., Limited (formerly I'rom Pharmaceutical Co., Limited)	Japan	100%*	100%*
Hormosan Pharma GmbH	Germany	100%+	100%+
Pharma Dynamics (Proprietary) Limited	South Africa	100%+	60%+
Lupin Australia Pty Limited	Australia	100%	100%
Lupin Holdings B.V.	Netherlands	100%	100%
Lupin Atlantis Holdings SA	Switzerland	100%	100%
Multicare Pharmaceuticals Philippines Inc.	Philippines	51%+	51%+
Lupin (Europe) Limited	UK	100%	100%
Lupin Pharma Canada Limited	Canada	100%+	100%+
Lupin Healthcare Limited	India	100%	100%
Generic Health Pty Limited	Australia	100%+	91.04%+
Bellwether Pharma Pty Limited	Australia	100%#	91.04%#
Max Pharma Pty Limited (upto 17 December 2014)	Australia	100%#	91.04%#
Lupin Mexico S.A. de C.V.	Mexico	100%+	100%+
Lupin Philippines Inc.	Philippines	100%+	100%+
Generic Health SDN. BHD.	Malaysia	100%+	100%+
Lupin Middle East FZ-LLC	UAE	100%	100%
Lupin GmbH (from 15 August 2013)	Switzerland	100%**	100%**
Lupin Inc. (from 27 June 2013)	USA	100%**	100%**
Lupin Farmaceutica do Brasil LTDA (formerly Farma World Importacao e Exportacao De Medicamentos LTDA – EPP) (from 17 December 2013)	Brazil	100%+	100%+
Nanomi B.V. (from 30 January 2014)	Netherlands	100%**	100%**
Laboratorios Grin S.A. de C.V., (from 30 September 2014)	Mexico	100%**	-
YL Biologics Ltd., (from 23 April 2014)	Japan	45%***	-

@ 97% interest held through Lupin Inc., USA from 31 December 2014 (80% from 31 March 2014).

+ Ownership interest held through Lupin Holdings B.V., Netherlands.

* Wholly owned subsidiary of Kyowa Pharmaceutical Industry Co., Limited, Japan.

Wholly owned subsidiaries of Generic Health Pty Limited, Australia.

** Wholly owned subsidiaries of Lupin Atlantis Holdings SA, Switzerland.

*** Jointly Controlled Entity of Lupin Atlantis Holdings SA, Switzerland (with Yoshindo Inc. having 55% share of interest).

The consolidated financial statements include the results of the aforesaid subsidiaries and there are no other bodies corporate / entities, where the Company holds more than 50% of the share capital or where the Company can control the composition of the Board of Directors / Governing Bodies of such entities, where the holding may be less than 50%.

31. Commitments:

a) Estimated amount of contracts remaining to be executed on capital account and not provided for, net of advances, Tangible assets ₹ 2459.7 million (previous year ₹ 2084.0 million) and Intangible assets ₹ 65.2 million (previous year ₹ 56.1 million).

b) Commitments for research activities amounting to ₹ 839.9 million (net of advances) (previous year ₹ 1028.9 million).

c) Other commitments – Non-cancellable operating and finance leases (Refer note 36).

d) There are no capital commitments at the jointly controlled entity of the Group as at the year end.

e) The Group is committed to operationally, technically and financially support the operations of its subsidiaries.

32. Contingent Liabilities:

		As at 31.03.2015	As at 31.03.2014
		₹ in million	₹ in million
a)	Income tax demands / matters on account of deductions / disallowances for earlier years, pending for appeals [₹ 49.7 million (previous year ₹ 49.7 million) consequent to department preferring appeals against the orders of the Appellate Authorities passed in favour of the Company]. Amount paid there against and included under note 15 "Long-Term Loans and Advances" ₹ 55.4 million (previous year ₹ 26.3 million).	826.4	173.2
b)	Excise duty, Service tax and Sales tax demands for input tax credit disallowances and demand for additional Entry Tax arising from dispute on applicable rate are in appeals and pending decisions. Amount paid there against and included under note 21 "Short-Term Loans and Advances" ₹ 28.5 million (previous year ₹ 30.4 million) and under note 15 "Long Term Loans and Advances" ₹ 2.5 million (previous year ₹ nil).	377.0	355.5
c)	Claims against the Company not acknowledged as debts [excluding interest (amount unascertained) in respect of a claim] for transfer charges of land, octroi duty, local body tax, employee claims, power, trade marks, pricing, indemnity, stamp duty and price reported under Medicaid for one subsidiary. Amount paid there against without admitting liability and included under note 21 "Short-Term Loans and Advances" ₹ 12.3 million (previous year ₹ 12.6 million).	6378.7	6223.2
d)	Counter guarantee given to GIDC in connection with repayment of loan sanctioned by a financial institution to a company, jointly promoted by an Association of Industries (of which, the Company is a member) and GIDC.	-	7.5
e)	During the year, the Company received a notice from the European Commission for alleged breach of the EU Antitrust Rules, whereby it has sought to levy a fine of Euro 40.0 Million (₹ 2687.6 million) on the Company in respect of an agreement entered into by the Company with Laboratories Servior, France, for sale of certain patent applications and IPs for the product Perindopril which the European Commission considered as anti-competitive. The Company, based on facts of the matter and legal advice received does not agree with the said notice / demand and is of the view that it has a strong case to defend itself. Accordingly, the Company has filed an appeal before the European General Court. A bank guarantee of Euro 40.0 million has been furnished to European Commission.		

There are no contingent liabilities at the jointly controlled entity of the Group as at the year end.

Future cash outflows in respect of the above, if any, is determinable only on receipt of judgement / decisions pending with the relevant authorities. The Group does not expect the outcome of the matters stated above to have a material adverse impact on the Group's financial condition, results of operations or cash flows.

The Group does not envisage any likely reimbursements in respect of the above.

The Company and its subsidiaries are involved in various legal proceedings, including product liability related claims, employment claims and other regulatory matters relating to conduct of its business. The Group carries product liability insurance policy with an amount it believes is sufficient for its needs. In respect of other claims, the Group believes, these claims do not constitute material litigation matters and with its meritorious defenses, the ultimate disposition of these matters will not have material adverse effect on its Consolidated Financial Statements.

33. Pre-operative expenses pending capitalisation included in Capital Work-In-Progress (Refer note 12) represent direct attributable expenditure for setting up of plants prior to the date of commencement of commercial production. The same will be capitalised on completion of projects and commencement of commercial operations. The details of the pre-operative expenses are:

Particulars	2014-15	2013-14
	₹ in million	₹ in million
Opening balance	182.2	222.6
Incurred during the current year:		
Salaries, allowances and contribution to funds	65.7	11.2
Legal and Professional Charges	6.3	0.3
Travelling and Conveyance	13.0	1.6
Others	16.3	4.4
Total	101.3	17.5
Less : Capitalised during the year	42.5	57.9
Closing balance	**241.0**	**182.2**

34. Segment Reporting:

i) Primary segment:

The Group operates exclusively in the Pharmaceutical business segment which is the only reportable business segment.

ii) Secondary segment data:

(Current year ₹ in million)

Particulars	India	USA	Japan	Others	Total
Revenue by Geographical Segment	33848.9	54747.3	13269.0	25834.9	127700.1
Carrying amount of Segment Assets	69236.1	18283.0	17075.6	25635.9	130230.6
Capital Expenditure	5035.7	578.6	1504.3	12558.5	19677.1

(Previous year ₹ in million)

Particulars	India	USA	Japan	Others	Total
Revenue by Geographical Segment	28641.0	48299.9	12997.9	22926.9	112865.7
Carrying amount of Segment Assets	50246.9	16406.6	16932.3	16755.0	100340.8
Capital Expenditure	3389.0	137.5	808.3	1357.2	5692.0

a) The segment revenue in geographical segments considered for disclosure is as follows:

i) Revenue within India includes sales to customers located within India and other operating income earned in India.

ii) Revenue outside India includes sales to customers located outside India and other operating income outside India.

b) Segment revenue comprises:

(Current year ₹ in million)

Particulars	India	USA	Japan	Others	Total
Sales (net of excise duty)	33586.2	54601.3	13239.0	24570.6	125997.1
Other Operating Income	262.7	146.0	30.0	1264.3	1703.0
Total Revenue	33848.9	54747.3	13269.0	25834.9	127700.1

(Previous year ₹ in million)

Particulars	India	USA	Japan	Others	Total
Sales (net of excise duty)	27999.2	48091.2	12954.7	21821.3	110866.4
Other Operating Income	641.8	208.7	43.2	1105.6	1999.3
Total Revenue	28641.0	48299.9	12997.9	22926.9	112865.7

35. Basic and Diluted Earnings per Share is calculated as under:

Particulars	2014-2015	2013-2014
Net Profit after minority interest attributable to equity shareholders (₹ in million)	24032.4	18363.7
Weighted average number of Equity Shares:		
- Basic	448868014	447982156
Add: Effect of dilutive issue of employees stock options (ESOPs) - converted during the year and ESOPs outstanding as at the year end	2846900	2262690
- Diluted	451714914	450244846
Earnings per Share (in ₹)		
- Basic	53.54	40.99
- Diluted	53.20	40.79

36. a) The Group procures equipments, vehicles and office premises under operating leases. The initial tenure of the lease is generally between 12 months to 60 months. The lease rentals recognised in the Consolidated Statement of Profit and Loss (Refer note 29) for the year are ₹ 626.3 million (previous year ₹ 550.3 million). The future minimum lease payments and payment profile of non-cancellable operating leases are as under:

Particulars	2014-2015	2013-2014
	₹ in million	₹ in million
Not later than one year	517.2	460.0
Later than one year but not later than five years	845.3	878.9
Later than five years	229.3	129.7
Total	1591.8	1468.6

b) Subsidiary companies in Japan and South Africa have future obligations under finance lease for procurement of Plant and Equipment and Vehicles which are payable as under:

(₹ in million)

Particulars	2014-2015		
	Present Value of minimum lease payment	Future Interest Cost	Minimum lease payment
Not later than one year	10.0	0.6	10.6
	(25.6)	(1.0)	(26.6)
Later than one year but not later than five years	1.0	0.1	1.1
	(11.3)	(0.5)	(11.8)
Later than five years	-	-	-
	(-)	(-)	(-)
Total	**11.0**	**0.7**	**11.7**
	(36.9)	(1.5)	(38.4)

Previous year figures are given in bracket.

37. Employees Stock Option Plans:

a) The Group implemented "Lupin Employees Stock Option Plan 2003" (ESOP 2003), "Lupin Employees Stock Option Plan 2005" (ESOP 2005), "Lupin Subsidiary Companies Employees Stock Option Plan 2005" (SESOP 2005), "Lupin Employees Stock Option Plan 2011" (ESOP 2011), "Lupin Subsidiary Companies Employees Stock Option Plan 2011" (SESOP 2011) in earlier years; and "Lupin Employees Stock Option Plan 2014" (ESOP 2014) and "Lupin Subsidiary Companies Employees Stock Option Plan 2014" (SESOP 2014) in the current year, as approved by the Shareholders of the Company and the Remuneration / Compensation / Nomination and Remuneration Committee of the Board of Directors. Details of the options granted during the year under the plans are as under:

Lupin Employees Stock Option Plan 2003 (ESOP 2003):

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
August 14, 2014	39250	1164.80	14.08.2014 to 14.08.2015
	39250	1164.80	14.08.2014 to 14.08.2016
	39250	1164.80	14.08.2014 to 14.08.2017
	39250	1164.80	14.08.2014 to 14.08.2018
	157000		
November 20, 2014	4000	724.68	20.11.2014 to 20.11.2015
	4000		

Lupin Employees Stock Option Plan 2005 (ESOP 2005):

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
August 14, 2014	9125	1164.80	14.08.2014 to 14.08.2015
	9125	1164.80	14.08.2014 to 14.08.2016
	9125	1164.80	14.08.2014 to 14.08.2017
	9125	1164.80	14.08.2014 to 14.08.2018
	36500		
November 20, 2014	4000	724.68	20.11.2014 to 20.11.2015
	4000		

Lupin Employees Stock Option Plan 2011 (ESOP 2011):

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
May 26, 2014	125	923.85	26.05.2014 to 26.05.2015
	125	923.85	26.05.2014 to 26.05.2016
	125	923.85	26.05.2014 to 26.05.2017
	125	923.85	26.05.2014 to 26.05.2018
	500		
August 14, 2014	155563	1164.80	14.08.2014 to 14.08.2015
	155563	1164.80	14.08.2014 to 14.08.2016
	155562	1164.80	14.08.2014 to 14.08.2017
	155562	1164.80	14.08.2014 to 14.08.2018
	622250		

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
October 08, 2014	1125	1368.05	08.10.2014 to 08.10.2015
	1125	1368.05	08.10.2014 to 08.10.2016
	1125	1368.05	08.10.2014 to 08.10.2017
	1125	1368.05	08.10.2014 to 08.10.2018
	4500		
November 20, 2014	42000	724.68	20.11.2014 to 20.11.2015
	42000		

Lupin Subsidiary Companies Employees Stock Option Plan 2011 (SESOP 2011):

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
April 02, 2014	7500	945.10	02.04.2014 to 02.04.2015
	7500	945.10	02.04.2014 to 02.04.2016
	7500	945.10	02.04.2014 to 02.04.2017
	7500	945.10	02.04.2014 to 02.04.2018
	30000		
May 13, 2014	6250	959.05	13.05.2014 to 13.05.2015
	6250	959.05	13.05.2014 to 13.05.2016
	6250	959.05	13.05.2014 to 13.05.2017
	6250	959.05	13.05.2014 to 13.05.2018
	25000		
July 02, 2014	3000	1049.55	02.07.2014 to 02.07.2015
	3000	1049.55	02.07.2014 to 02.07.2016
	3000	1049.55	02.07.2014 to 02.07.2017
	3000	1049.55	02.07.2014 to 02.07.2018
	12000		
August 05, 2014	10050	1177.60	05.08.2014 to 05.08.2015
	10050	1177.60	05.08.2014 to 05.08.2016
	10050	1177.60	05.08.2014 to 05.08.2017
	10050	1177.60	05.08.2014 to 05.08.2018
	40200		
August 14, 2014	63678	1164.80	14.08.2014 to 14.08.2015
	63678	1164.80	14.08.2014 to 14.08.2016
	63677	1164.80	14.08.2014 to 14.08.2017
	63677	1164.80	14.08.2014 to 14.08.2018
	254710		
November 11, 2014	8225	1430.95	11.11.2014 to 11.11.2015
	8225	1430.95	11.11.2014 to 11.11.2016
	8225	1430.95	11.11.2014 to 11.11.2017
	8225	1430.95	11.11.2014 to 11.11.2018
	32900		
November 20, 2014	6675	1449.35	20.11.2014 to 20.11.2015
	6675	1449.35	20.11.2014 to 20.11.2016
	6675	1449.35	20.11.2014 to 20.11.2017
	6675	1449.35	20.11.2014 to 20.11.2018
	26700		
February 11, 2015	6925	1562.95	11.02.2015 to 11.02.2016
	6925	1562.95	11.02.2015 to 11.02.2017
	6925	1562.95	11.02.2015 to 11.02.2018
	6925	1562.95	11.02.2015 to 11.02.2019
	27700		

Lupin Employees Stock Option Plan 2014 (ESOP 2014):

Grant Date	No. of Options	Exercise Price ₹	Vesting Period
November 20, 2014	59900	2.00	20.11.2014 to 20.11.2015
	59900	2.00	20.11.2014 to 20.11.2016
	59899	2.00	20.11.2014 to 20.11.2017
	59899	2.00	20.11.2014 to 20.11.2018
	239598		
January 27, 2015	5106	2.00	27.01.2015 to 27.01.2016
	5106	2.00	27.01.2015 to 27.01.2017
	5106	2.00	27.01.2015 to 27.01.2018
	5106	2.00	27.01.2015 to 27.01.2019
	20424		

The options are granted at an exercise price, which is in accordance with the relevant SEBI guidelines in force, at the time of such grants. Each option entitles the holder to exercise the right to apply for and seek allotment of one equity share of ₹ 2 each. The options have vesting periods as stated above in accordance with the vesting schedule as per the said plans with an exercise period of ten years from the respective grant dates.

The particulars of the options granted and lapsed under the Schemes are as below:

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
	Nos.	Nos.
Lupin Employees Stock Option Plan 2003 (ESOP 2003):		
Options outstanding as at the beginning of the year	539389	763615
Add: Options granted during the year	161000	50000
Less: Options lapsed during the year	14000	-
Less: Options exercised during the year	343389	274226
Options outstanding as at the year end	343000	539389

During the year, the Company terminated the offering of fresh grants under the above plan resulting in termination of 745 options which were not granted upto the date of termination. Options already granted under the said plan would continue to be in force in terms of their grant.

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
Lupin Employees Stock Option Plan 2005 (ESOP 2005):		
Options outstanding as at the beginning of the year	494529	751920
Add: Options granted during the year	40500	-
Less: Options lapsed during the year	6750	4875
Less: Options exercised during the year	82975	252516
Options outstanding as at the year end	445304	494529

During the year, the Company terminated the offering of fresh grants under the above plan resulting in termination of 4200 options which were not granted upto the date of termination. Options already granted under the said plan would continue to be in force in terms of their grant.

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
Lupin Subsidiary Companies Employees Stock Option Plan 2005 (SESOP 2005):		
Options outstanding as at the beginning of the year	364133	430119
Add: Options granted during the year	-	-
Less: Options lapsed during the year	220	-
Less: Options exercised during the year	130377	65986
Options outstanding as at the year end	233536	364133

During the year, the Company terminated the offering of fresh grants under the above plan resulting in termination of 7190 options which were not granted upto the date of termination. Options already granted under the said plan would continue to be in force in terms of their grant.

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
Lupin Employees Stock Option Plan 2011 (ESOP 2011):		
Options outstanding as at the beginning of the year	2737539	2259047
Add: Options granted during the year	669250	946250
Less: Options lapsed during the year	159664	219062
Less: Options exercised during the year	538774	248696
Options outstanding as at the year end	2708351	2737539
Lupin Subsidiary Companies Employees Stock Option Plan 2011 (SESOP 2011):		
Options outstanding as at the beginning of the year	429033	306780
Add: Options granted during the year	449210	185090
Less: Options lapsed during the year	61283	57950
Less: Options exercised during the year	17016	4887
Options outstanding as at the year end	799944	429033

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
	Nos.	Nos.
Lupin Employees Stock Option Plan 2014 (ESOP 2014):		
Options outstanding as at the beginning of the year	-	-
Add: Options granted during the year	260022	-
Less: Options lapsed during the year	5783	-
Less: Options exercised during the year	-	-
Options outstanding as at the year end	254239	-

b. The Group has followed the intrinsic value based method of accounting for stock options granted after April 1, 2005 based on Guidance Note on Accounting for Employee Share-based Payments, issued by the Institute of Chartered Accountants of India (ICAI). Had the compensation cost for the Group's stock based compensation plans been determined in the manner consistent with the fair value approach as described in the said Guidance Note, the Group's net income would be lower by ₹ 444.7 million (previous year ₹ 291.5 million) and earnings per share as reported would be as indicated below:

Particulars	Year Ended 31.03.2015	Year Ended 31.03.2014
	₹ in million	₹ in million
Net profit as reported	24032.4	18363.7
Less: Total stock-based employee compensation expense determined under fair value based method	501.4	310.9
Add: Total stock-based employee compensation expense determined under intrinsic value based method	56.7	19.4
Adjusted net profit	23587.7	18072.2
Basic earnings per share		
- As reported (in ₹)*	53.54	40.99
- Adjusted (in ₹)	52.55	40.34
Diluted earnings per share		
- As reported (in ₹)*	53.20	40.79
- Adjusted (in ₹)	52.22	40.14

* Refer note 35

The fair value of each option granted during the year is estimated on the date of grant based on the following assumptions:

Particulars	Grant Date	Dividend Yield (%)	Expected life (years)	Risk Free interest rate (%)	Volatility (%)
ESOP 2003 Plan	August 14, 2014	0.70	6.25	8.72	30.32
	November 20, 2014	0.70	5.50	8.23	26.93
ESOP 2005 Plan	August 14, 2014	0.70	6.25	8.72	30.32
	November 20, 2014	0.70	5.50	8.23	26.93
ESOP 2011 Plan	May 26, 2014	0.70	6.25	8.65	30.96
	August 14, 2014	0.70	6.25	8.72	30.32
	October 08, 2014	0.70	6.25	8.55	29.95
	November 20, 2014	0.70	5.50	8.23	26.93
SESOP 2011 Plan	April 02, 2014	0.70	6.25	9.07	31.71
	May 13, 2014	0.70	6.25	8.84	31.05
	July 02, 2014	0.70	6.25	8.66	30.59
	August 05, 2014	0.70	6.25	8.69	30.37
	August 14, 2014	0.70	6.25	8.72	30.32
	November 11, 2014	0.70	6.25	8.25	29.52
	November 20, 2014	0.70	6.25	8.23	29.31
	February 11, 2015	0.70	6.25	7.75	28.56
ESOP 2014 Plan	November 20, 2014	0.70	6.25	8.23	29.31
	January 27, 2015	0.70	6.25	7.75	28.61

38. Stock Appreciation Rights:

During the years 2011-12 and 2012-13, the Company has granted Stock Appreciation Rights ("SARs") to certain eligible employees in accordance with Lupin Employees Stock Appreciation Rights Scheme 2011 ("LESARs 2011") approved by the Board of Directors (Board) at their Board Meeting held on September 13, 2011. Under the scheme, eligible employees are entitled to receive appreciation in value of shares on completion of the vesting period.

The Scheme is administered through the Lupin Employees Benefit Trust (the "Trust") as settled by the Company. The Trust is administered by an independent Trustee. At the end of the vesting period of 3 years, the equity shares will be sold in the market by the Trust and the appreciation on the same (if any) will be distributed to the said employees, subject to vesting conditions.

The Company has been submitting required details with stock exchanges in terms of the circulars issued by SEBI in this regard. During the year SEBI vide its circular no. CIR/CFD/POLICYCELL/3/2014 dated June 27, 2014 has extended the timelines for alignment of the Scheme till the new regulations are notified, continuing the prohibition on acquiring securities from the secondary market.

The new regulation viz: Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 ('the Regulation') was notified on October 28, 2014, pursuant to which the existing schemes are to be aligned within one year of the effective date of the Regulation. During the year, the Trust has distributed the benefits of SARs to the eligible employees in terms of LESARs 2011 and has not acquired any shares from the secondary market.

As approved by the Board, the Company had, prior to the SEBI circular no. CIR/CFD/DIL/3/2013 dated January 17, 2013 advanced an interest free loan to the Trust during the years 2011-12 and 2012-13 to acquire appropriate number of Equity Shares of the Company from the market on the grant date of SARs and the loan outstanding as at the balance sheet date aggregating to ₹ nil (previous year ₹ 258.0 million) is included under "Long-Term Loans and Advances" (Refer note 15) and ₹ 251.3 million (previous year ₹ 218.9 million) is included under "Short-Term Loans and Advances" (Refer note 21).

The particulars of the SARs assigned, lapsed and redeemed under the Scheme are as below:

Particulars	**Year Ended 31.03.2015**	Year Ended 31.03.2014
Lupin Employees Stock Appreciation Rights Scheme 2011:		
SARs outstanding as at the beginning of the year	843396	860098
Less: SARs lapsed during the year	13873	16702
Less: SARs redeemed during the year	420931	-
SARs outstanding as at the year end	408592	843396

The related compensation cost for outstanding SARs and in case of redeemed SARs upto the date of redemption amounting to ₹ 620.1 million (previous year ₹ 191.6 million) has been recognized as Employee Benefits Expense and the corresponding credit is included under "Reserves and Surplus" as Employee Stock Appreciation Rights Outstanding. In respect of SARs redeemed during the year, the corresponding amount of ₹ 379.0 million (previous year ₹ nil) has been transferred from Employee Stock Appreciation Rights Outstanding to General Reserve. Had the compensation cost for the Company's stock based compensation plans been determined in the manner consistent with the fair value approach as described in the Guidance Note on Accounting for Employee Share-based Payments issued by ICAI, the Group's net income would be higher by ₹ 587.3 million (previous year by ₹ 110.3 million) and earnings per share as reported would be as indicated below:

Particulars	**Year Ended 31.03.2015**	Year Ended 31.03.2014
	₹ in million	₹ in million
Net profit as reported	24032.4	18363.7
Less: Total stock-based employee compensation expense determined under fair value based method	32.8	81.3
Add: Total stock-based employee compensation expense determined under intrinsic value based method	620.1	191.6
Adjusted net profit	24619.7	18474.0
Basic earnings per share		
- As reported (in ₹)*	53.54	40.99
- Adjusted (in ₹)	54.85	41.24
Diluted earnings per share		
- As reported (in ₹)*	53.20	40.79
- Adjusted (in ₹)	54.50	41.03

* Refer note 35

39. Post Employment Benefits:

(i) Defined Contribution Plans:

The Group makes contributions towards provident fund, superannuation fund and other retirement benefits to a defined contribution retirement benefit plan for qualifying employees. Under the plan, the Group is required to contribute a specified percentage of payroll cost to the retirement benefit plan to fund the benefits.

The Group recognised ₹ 454.4 million (previous year ₹ 360.4 million) for superannuation contribution and other retirement benefit contributions in the Consolidated Statement of Profit and Loss.

The contributions payable to these plans by the Group are at rates specified in the rules of the schemes.

The Company recognised ₹ 147.5 million (previous year ₹ 92.5 million) for provident fund contributions in the Consolidated Statement of Profit and Loss.

(ii) Defined Benefit Plan:

a) The Company

A) The Company makes annual contributions to the Group Gratuity cum Life Assurance Schemes administered by the LIC of India, a funded defined benefit plan for qualifying employees. The scheme provides for payment as under:

i) On normal retirement / early retirement / withdrawal / resignation:
As per the provisions of the Payment of Gratuity Act, 1972 with vesting period of 5 years of service.

ii) On death in service:
As per the provisions of the Payment of Gratuity Act, 1972 without any vesting period.

In addition to the above mentioned scheme, the Company also pays additional gratuity as an ex-gratia and the said amount is provided as non-funded liability based on actuarial valuation.

The most recent actuarial valuation of plan assets and the present value of the defined benefit obligation for gratuity were carried out as at March 31, 2015. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

Based on the actuarial valuation obtained in this respect, the following table sets out the status of the gratuity plan and the amounts recognised in the Group's financial statements as at balance sheet date:

Sr. No.	Particulars	Gratuity (Funded)		Gratuity (Unfunded)	
		As on 31.03.2015	As on 31.03.2014	**As on 31.03.2015**	As on 31.03.2014
		₹ in million	₹ in million	**₹ in million**	₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation:**				
	Current service cost	136.2	102.6	92.3	70.8
	Past service cost	-	-	-	-
	Interest cost	57.5	45.4	39.7	29.0
	Actuarial loss / (gain)	75.1	(27.0)	10.2	(28.3)
	Benefits paid	(52.8)	(63.5)	-	-
	PVO at the beginning of the year	652.4	594.9	431.8	360.3
	PVO at the end of the year	868.4	652.4	574.0	431.8
II)	**Change in fair value of plan assets:**				
	Expected return on plan assets	54.2	45.3	-	-
	Actuarial gain / (loss)	2.0	4.2	-	-
	Contributions by the employer	76.5	125.5	-	-
	Benefits paid	(52.8)	(63.5)	-	-
	Fair value of plan assets at the beginning of the year	580.9	469.4	-	-
	Fair value of plan assets at the end of the year	660.8	580.9	-	-
III)	**Reconciliation of PVO and fair value of plan assets:**				
	PVO at end of the year	868.4	652.4	574.0	431.8
	Fair Value of plan assets at the end of the year	660.8	580.9	-	-
	Funded status	(207.6)	(71.5)	(574.0)	(431.8)

Sr. No.	Particulars	Gratuity (Funded)		Gratuity (Unfunded)	
		As on 31.03.2015 ₹ in million	As on 31.03.2014 ₹ in million	As on 31.03.2015 ₹ in million	As on 31.03.2014 ₹ in million
	Unrecognised actuarial gain / (loss)	-	-	-	-
	Net liability recognised in the balance sheet	(207.6)	(71.5)	(574.0)	(431.8)
IV)	**Net cost for the year**:				
	Current service cost	136.2	102.6	92.3	70.8
	Past service cost	-	-	-	-
	Interest cost	57.5	45.4	39.7	29.0
	Expected return on plan assets	(54.2)	(45.3)	-	-
	Actuarial losses / (gain)	73.1	(31.2)	10.2	(28.3)
	Total expense recognised in the Statement of Profit and Loss (Refer note 27)	212.6	71.5	142.2	71.5
V)	**Category of assets as at the end of the year**:				
	Insurer Managed Funds (100%) (Fund is Managed by LIC as per IRDA guidelines, category-wise composition of the plan assets is not available)	660.8	580.9	NA	NA
VI)	**Actual return on the plan assets**:	56.2	49.5	NA	NA
VII)	**Assumptions used in accounting for the gratuity plan**:				
	Discount rate (%)	7.8	9.2	7.8	9.2
	Salary escalation rate (%)	6.0	6.0	6.0	6.0
	Expected rate of return on plan assets (%)	9.1 & 9.2	9.1	NA	NA
VIII)	**Estimate of amount of contribution in immediate next year**	207.6	71.5	NA	NA

The estimates of salary escalation, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

(₹ in million)

Gratuity (Funded)	Year Ended				
	31.03.2015	31.03.2014	31.03.2013	31.03.2012	31.03.2011
Experience adjustment					
- On plan liabilities	(15.3)	32.6	6.1	90.5	#
- On plan assets	2.0	4.2	0.1	2.3	#
Present value of benefit obligation	868.4	652.4	594.9	462.7	384.6
Fair value of plan assets	660.8	580.9	469.4	417.7	365.4
Excess of (obligation over plan assets) / plan assets over obligation	(207.6)	(71.5)	(125.5)	(45.0)	(19.2)

Experience adjustment information in respect of previous one year is not available, hence not disclosed.

B) The provident fund plan of the Company, except at two plants, is operated by the "Lupin Limited Employees Provident Fund Trust" (the "Trust"). Eligible employees receive benefits from the said Provident Fund. Both the employees and the Company make monthly contributions to the Provident Fund Plans equal to a specified percentage of the covered employee's salary. The minimum interest rate payable by the Trust to the beneficiaries every year is being notified by the Government. The Company has an obligation to make good the shortfall, if any, between the return from the investments of the Trust and the notified interest rate.

The ASB Guidance on Implementing AS-15, Employee Benefits (revised 2005) issued by Accounting Standards Board (ASB) states that benefit plans involving employer established provident funds, which require interest shortfalls to be recompensed are to be considered as defined benefit plans. As per the Guidance Note from the Actuarial Society of India, the Company has obtained the actuarial valuation of interest rate obligation in respect of Provident Fund as at March 31, 2015 and shortfall aggregating ₹ nil (previous year ₹ 9.0 million) has been provided for. The Company has an obligation to service the shortfall on account of interest generated by the fund and on maturity of fund investments and hence the same has been classified as Defined Benefit Plan.

The Company recognised ₹ 266.4 million (previous year ₹ 257.0 million) for provident fund contributions in the Consolidated Statement of Profit and Loss.

Based on the actuarial valuation obtained in this respect, the following table sets out the status of the provident fund plan and the amounts recognised in the Group's financial statements as at balance sheet date:

Sr. No.	Particulars	Provident Fund (Funded)	
		As on 31.03.2015	As on 31.03.2014
		₹ in million	₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation:**		
	Current service cost	1068.4	885.6
	Past service cost	-	-
	Interest cost	0.8	1.6
	Actuarial loss / (gain)	(9.8)	(12.5)
	Benefits paid	(286.2)	(224.9)
	PVO at the beginning of the year	3388.9	2739.1
	PVO at the end of the year	4162.1	3388.9
II)	**Change in fair value of plan assets:**		
	Expected return on plan assets	329.7	243.2
	Adjustment to opening balance	(3.5)	-
	Actuarial gain / (loss)	-	-
	Contributions by the employer	742.2	642.4
	Benefits paid	(286.2)	(224.9)
	Fair value of plan assets at the beginning of the year	3379.9	2719.2
	Fair value of plan assets at the end of the year	4162.1	3379.9
III)	**Reconciliation of PVO and fair value of plan assets:**		
	PVO at end of the year	4162.1	3388.9
	Fair Value of plan assets at the end of the year	4162.1	3379.9
	Funded status	-	(9.0)
	Unrecognised actuarial gain / (loss)	-	-
	Net liability recognised in the balance sheet (Refer note 7)	-	(9.0)
IV)	**Net cost for the year:**		
	Current service cost	1068.4	885.6
	Past service cost	-	-
	Interest cost	0.8	1.6
	Expected return on plan assets	(329.7)	(243.2)
	Actuarial losses / (gain)	(6.3)	(12.5)
	Interest expense pertaining to the Trust	(742.2)	(642.4)
	Net expense recognised in the Statement of Profit and Loss (Refer note 27)	(9.0)	(10.9)
V)	**Category of assets as at the end of the year:**		
	Investment in PSU bonds	21%	22%
	Investment in Government Securities	45%	44%
	Bank Special Deposit	6%	6%
	Investment in other securities	26%	26%
	Bank Savings Deposit	2%	2%
VI)	**Actual return on the plan assets:**	329.7	243.2
VII)	**Assumptions used in accounting for the provident fund plan:**		
	Discount rate (%)	7.8	9.2
	Salary escalation rate (%)	6.0	6.0
	Expected rate of return on plan assets (%)	8.8	8.8

b) **Kyowa Pharmaceutical Industry Co., Limited, Japan**

The Group's subsidiary at Japan has retirement plan to cover all its employees. The plan consist of a defined benefit non funded pension plan (referred as "plan").

Under the plan, employees are entitled to benefits based on level of salaries, length of service and certain other factors at the time of retirement or termination.

The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

Retirement allowances for directors are provided for liability of the amount that would be required if all directors retired at the balance sheet date.

The following table sets out the status of the retirement plan and the amounts recognised in the Group's financial statements as at balance sheet date:

Sr. No.	Particulars	Lump sum Retirement Benefits (non funded)	
		As on 31.03.2015	As on 31.03.2014
		₹ in million	₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation:**		
	Current service cost	19.8	15.6
	Interest cost	1.1	1.6
	Actuarial (gain) / loss	8.4	11.2
	Benefits paid	(4.4)	(4.5)
	Foreign exchange translation difference	(16.8)	1.2
	PVO at the beginning of the year	138.5	113.4
	PVO at end of the year	146.6	138.5
II)	**Reconciliation of PVO and fair value of plan assets:**		
	PVO at end of the year	146.6	138.5
	Fair Value of plan assets at end of the year	-	-
	Funded status	(146.6)	(138.5)
	Unrecognised actuarial gain / (loss)	-	-
	Net asset / (liability) recognised in the balance sheet	(146.6)	(138.5)
III)	**Net cost for the year:**		
	Current service cost	19.8	15.6
	Interest cost	1.1	1.6
	Actuarial (gain) / losses	8.4	11.2
	Total expense recognised in the Consolidated Statement of Profit and Loss (Refer note 27)	29.3	28.4
IV)	**Assumptions used in accounting for the retirement benefit plan:**		
	Discount rate (%)	0.7	0.9
	Salary escalation rate (%)	-	-
	Expected rate of return on plan assets (%)	-	-

Liability of lump sum retirement benefit as above along with liability for retirement benefits of directors ₹ 20.4 million (previous year ₹ 18.2 million) is shown under "Long-Term Provisions" (Refer note 7).

(₹ in million)

	Year Ended				
	31.03.2015	31.03.2014	31.03.2013	31.03.2012	31.03.2011
Experience adjustment					
- On plan liabilities	7.8	3.9	1.3	2.0	#
- On plan assets	-	-	-	-	#
Present value of benefit obligation	146.6	138.5	113.4	108.5	81.1
Fair value of plan assets	-	-	-	-	-
Excess of obligation over plan assets	(146.6)	(138.5)	(113.4)	(108.5)	(81.1)

Experience adjustment information in respect of previous one year is not available, hence not disclosed.

c) **Kyowa CritiCare Co., Limited, Japan (formerly I'rom Pharmaceutical Co., Limited)**

The Group's another subsidiary at Japan has retirement plan to cover its employees.

Under the plan, employees are entitled to benefits based on level of salaries, length of service and certain other factors at the time of retirement or termination.

The most recent actuarial valuation of the present value of the defined benefit obligation for retirement benefits were carried out as at March 31, 2015. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

The following table sets out the status of the retirement plan and the amounts recognised in the Group's financial statements as at balance sheet date:

Sr. No.	Particulars	Lump sum Retirement Benefits (non funded)	
		As on 31.03.2015	As on 31.03.2014
		₹ in million	₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation:**		
	Current Service Cost	24.0	26.9
	Interest Cost	1.3	2.8
	Actuarial (gain) / loss	0.8	5.9
	Prior Service Cost	5.9	(2.9)
	Benefits paid	(37.1)	(36.8)
	Foreign exchange translation difference	(29.1)	4.8
	PVO at beginning of the year	268.9	268.2
	PVO at the end of the year	234.6	268.9
II)	**Reconciliation of PVO and fair value of plan assets:**		
	PVO at end of the year	234.6	268.9
	Fair Value of planned assets at end of the year	-	-
	Funded status	(234.6)	(268.9)
	Unrecognised actuarial gain / (loss)	-	-
	Net asset / (liability) recognised in the balance sheet	(234.6)	(268.9)
III)	**Net cost for the year:**		
	Current Service cost	24.0	26.9
	Interest cost	1.3	2.8
	Actuarial (gain) / losses	0.8	5.9
	Amortization of prior service cost	5.9	(2.9)
	Total expense recognised in the Consolidated Statement of Profit and Loss (Refer note 27)	32.0	32.6
IV)	**Assumptions used in accounting for retirement benefit plans:**		
	Discount rate (%)	0.4	1.0
	Salary escalation rate (%)	-	-
	Expected rate of return on plan assets (%)	-	-

Liability of lump sum retirement benefit as above along with liability for retirement benefits of directors ₹ 2.3 million (previous year ₹ nil) is shown under "Long-Term Provisions" (Refer note 7).

(₹ in million)

	Year Ended				
	31.03.2015	31.03.2014	31.03.2013	31.03.2012	31.03.2011
Experience adjustment					
- On plan liabilities	0.8	(5.9)	(3.5)	#	NA
- On plan assets	-	-	-	-	NA
Present value of benefit obligation	234.6	268.9	268.2	283.4	NA
Fair value of plan assets	-	-	-	-	NA
Excess of obligation over plan assets	(234.6)	(268.9)	(268.2)	(283.4)	NA

Experience adjustment information in respect of one year is not available, hence not disclosed.

d) Multicare Pharmaceuticals Philippines Inc., Philippines

The Group's subsidiary at Philippines makes annual contributions to a private bank to fund defined benefit plan for qualifying employees. The most recent actuarial valuation of plan assets and the present value of the defined benefit obligation for retirement benefit were carried out as at March 31, 2015. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

The following table sets out the status of the retirement plan and the amounts recognised in the Group's financial statements as at balance sheet date:

Sr. No.	Particulars	Retirement Benefits (funded)	
		As on 31.03.2015	As on 31.03.2014
		₹ in million	₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation:**		
	Current service cost	9.5	9.0
	Interest cost	3.0	3.6
	Actuarial (gain) / loss	(11.2)	(29.4)
	Benefits paid	(0.7)	(1.0)
	Foreign exchange translation difference	2.4	0.9
	PVO at the beginning of the year	52.8	69.7
	PVO at end of the year	55.7	52.8
II)	**Change in fair value of plan assets:**		
	Expected return on plan assets	1.7	1.4
	Actuarial gain / (loss)	1.2	(₹ 22674)
	Contributions by the employer	-	6.8
	Benefits paid	(0.7)	(1.0)
	Foreign exchange translation difference	1.4	(0.1)
	Fair value of plan assets at beginning of the year	30.8	23.7
	Fair value of plan assets at end of the year	34.4	30.8
III)	**Reconciliation of PVO and fair value of plan assets:**		
	PVO at end of year	55.7	52.8
	Fair Value of plan assets at end of year	34.4	30.7
	Funded status	(21.3)	(22.1)
	Unrecognised actuarial (loss) / gain	-	-
	Net asset / (liability) recognised in the balance sheet	(21.3)	(22.1)
IV)	**Net cost for the year:**		
	Current Service cost	9.5	9.0
	Interest cost	3.0	3.6
	Expected return on plan assets	(1.7)	(1.4)
	Actuarial (gain) / losses	(12.4)	(29.4)
	Total expense recognised in the Consolidated Statement of Profit and Loss	(1.7)	(18.2)
V)	**Category of assets as at the end of the year:**		
	Investment in government bonds	15%	23%
	Investment in unit investment trust fund	40%	37%
	Investment in debt instruments – bonds	15%	18%
	Investment in equity and other securities	21%	18%
	Cash and cash equivalents	9%	4%
VI)	**Actual return on the plan assets**	3.0	1.4
VII)	**Assumptions used in accounting for retirement benefit plan:**		
	Discount rate (%)	5.1	5.5
	Salary escalation rate (%)	7.0	7.0
	Expected rate of return on plan assets (%)	5.4	7.0

(₹ in million)

	Year Ended				
	31.03.2015	31.03.2014	31.03.2013	31.03.2012	31.03.2011
Experience adjustment					
- On plan liabilities	(6.0)	(1.7)	19.9	0.3	#
- On plan assets	1.2	₹ 22674	1.3	₹ (33109)	#
Present value of benefit obligation	55.7	52.8	69.7	34.6	22.8
Fair value of plan assets	34.4	30.7	23.7	12.0	10.0
Excess of obligation over plan assets	(21.3)	(22.1)	(46.0)	(22.6)	(12.8)

Experience adjustment information in respect of previous one year is not available, hence not disclosed.

e) **Laboratorios Grin S.A. de C.V., Mexico**

The Company has retirement plan to cover its employees which are required by law.

Under the plan, employees are entitled to benefits based on level of salaries, length of service and certain other factors at the time of retirement or termination.

The most recent actuarial valuation of the present value of the defined benefit obligation for retirement benefits were carried out as at March 31, 2015. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

The following table sets out the status of the retirement plan and the amounts recognised in the Company's financial statements as at March 31, 2015.

Sr. No.	Particulars	Lump sum Retirement Benefits (non funded)
		As on 31.03.2015
		₹ in million
I)	**Reconciliation in present value of obligations ('PVO') – defined benefit obligation :**	
	Current Service Cost	1.0
	Interest Cost	0.6
	Actuarial (gain) / losses	(0.1)
	Benefits paid	0.5
	Foreign exchange translation difference	(1.4)
	Past service cost	(0.4)
	PVO at the beginning of the year	12.5
	PVO at end of the year	12.7
II)	**Reconciliation of PVO and fair value of plan assets:**	
	PVO at end of year	12.7
	Fair Value of planned assets at end of year	-
	Funded status	-
	Unrecognised actuarial gain / (loss)	-
	Net asset / (liability) recognised in the balance sheet	12.7
III)	**Net cost for the year ended March 31,2015 :**	
	Current Service cost	1.0
	Past service cost	(0.4)
	Interest cost	0.6
	Actuarial (gain) / losses	(0.1)
	Benefits paid	0.5
	Expected return on plan assets	-
	Net cost	1.6
IV)	**Assumption used in accounting for the plans:**	
	Discount rate (%)	6.8
	Salary escalation rate (%)	5.3
	Expected rate of return on plan assets (%)	-

(₹ in million)

	Year Ended				
	31.03.2015	31.03.2014	31.03.2013	31.03.2012	31.03.2011
Experience adjustment					
- On plan liabilities	12.7	#	#	#	#
- On plan assets	-	#	#	#	#
Present value of benefit obligation	12.7	#	#	#	#
Fair value of plan assets	-	#	#	#	#
Excess of obligation over plan assets	(12.7)	#	#	#	#

Information in respect of previous four years is not available, hence not disclosed.

40. (i) The Company has entered into foreign currency forward and futures contracts which are not intended for trading or speculative purposes but for hedge purposes to establish the amount of reporting currency required or available at the settlement date of certain payables. The following are the outstanding foreign currency forward contracts entered into by the Company:

Currency	Amount		Buy or Sell	Cross Currency
	As on 31.03.2015	As on 31.03.2014		
USD	-	10149602	Buy	INR

(ii) The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise are given below:

a. Amount receivable in foreign currency on account of the following:

Particulars	Foreign Currency	As on 31.03.2015		As on 31.03.2014	
		₹ in million	Amount in Foreign Currency	₹ in million	Amount in Foreign Currency
Export of goods					
	AUD	25.5	535690	31.9	574748
	ACUD	16.7	267382	9.1	152575
	EURO	350.9	5222949	405.8	4930367
	JPY	-	-	1.0	1768559
	RUB	₹ 2126	1961	-	-
	USD	3369.0	53900315	3247.4	54200582
Deposits with banks	USD	-	-	3170.2	52970000
Interest receivable on bank fixed deposits	USD	-	-	24.6	410691
Other receivables					
	JPY	27.5	52776791	6.9	11727001
	UZS	0.1	2251420	0.1	2973852
	EURO	263.8	3156620	7.1	86818
	USD	212.9	3406643	759.8	12680846
	RUB	0.7	611994	0.1	47325
	KZT	1.0	2826041	1.9	5710111
	CAD	0.6	12121	-	-
	GBP	48.4	523094	-	-
	RMB	5.5	542456	3.4	348403
	UAH	3.4	1248759	0.1	25879
	CHF	38.2	573238	-	-
	AUD	5.4	113274	-	-

b. Amount payable in foreign currency on account of the following:

Particulars	Foreign Currency	As on 31.03.2015		As on 31.03.2014	
		₹ in million	Amount in Foreign Currency	₹ in million	Amount in Foreign Currency
Import of goods and services					
	USD	2431.2	39202196	626.9	10532002
	GBP	18.9	205529	18.5	185281
	EURO	378.4	5468187	392.7	4903537
	AUD	1.1	22726	0.1	929
	CHF	120.6	1857888	1.2	17808
	JPY	0.3	495850	1.6	2807377
	SEK	-	-	0.2	22593
	CAD	₹ 10586	216	1.8	33296
	MYR	2.0	118555	-	-
	ZAR	0.2	30100	-	-
Other payables					
	USD	271.0	4317173	289.4	4830371
	RUB	1.0	903873	0.5	297112
	GBP	5.7	61500	-	-
	JPY	₹ 24484	46972	0.3	500000
	BRL	-	-	0.5	18684
	KZT	0.2	451218	0.4	1120778
	ACUD	0.8	12354	0.9	15187
	UAH	2.8	1040844	2.7	489197
	EURO	65.0	967963	51.5	631016
	AUD	-	-	9.8	176834
	CHF	20.4	314317	3.1	46044
	AED	-	-	0.3	18594
	PHP	27.1	19403305	-	-
	RMB	-	-	₹ 10224	1060
	UZS	-	-	0.1	4809250
	ZAR	5977.6	1167833450	-	-

41. Details of Derivative Contracts:

The Company enters into forward and option contracts in order to hedge and manage its foreign currency exposures towards future export earnings. Such derivative contracts are entered into by the Company for hedging purposes only, and are accordingly classified as cash flow hedges.

The category wise break-up of outstanding derivative contracts entered into by the Company is as under:

(Amount in million)

Particulars	Currency	As at 31.03.2015	As at 31.03.2014	Cross Currency
Forward contracts	USD	333.0	129.0	INR
Option contracts	USD	-	0.8	INR

The changes in the fair value of the derivative contracts during the year ended March 31, 2015, aggregating ₹ 92.6 million (previous year ₹ 265.5 million) designated and effective as hedges have been credited to the Cash Flow Hedge Reserve and ₹ 42.6 million (previous year ₹ 36.8 million) is credited to the Consolidated Statement of Profit and Loss, being the ineffective portion thereof.

42. The aggregate amount of revenue expenditure incurred by the Group during the year on Research and Development and shown in the respective heads of account is ₹ 10987.8 million (previous year ₹ 9294.1 million).

43. a) During the previous year, the Company purchased 100% stake consisting of Equity and Capital contribution of Lupin Atlantis Holdings SA, Switzerland (LAHSA) from its wholly owned subsidiary Lupin Holdings B.V., Netherlands at a total cost of ₹ 2993.7 million pursuant to which LAHSA became direct wholly owned subsidiary of the Company. During the year, the Company has made additional Capital Contribution of ₹ 7982.8 million in LAHSA.

Further, the Company invested an additional amount of ₹ 24.8 million (previous year ₹ nil) in Lupin Middle East FZ-LLC, UAE, a wholly owned subsidiary.

b) During the year, the Company, through its wholly owned subsidiary LAHSA acquired / subscribed to the equity stake of the following subsidiaries / jointly controlled entity:

i) 45% equity stake in YL Biologics Ltd., Japan a jointly controlled entity at a total cost of ₹ 33.0 million. Initial investment was ₹ 80.8 million of which ₹ 47.8 million was refunded subsequently in terms of resolution passed at extraordinary shareholders meeting of YL Biologics Ltd. on November 14, 2014 which has been accounted as reduction in investment by LAHSA.

ii) 100% equity stake in Laboratorios Grin S.A. de C.V., Mexico at a total cost of ₹ 6149.6 million.

iii) Additional Investment in Nanomi B.V., Netherlands at a total cost of ₹ nil (previous year ₹ 857.0 million for 100% equity stake).

iv) Additional investment in Lupin Inc., USA at a total cost of ₹ 542.1 million (previous year ₹ 325.0 million for 100% equity stake) including additional paid-in capital – securities premium of ₹ 542.1 million (previous year ₹ 321.9 million).

v) Additional investment in Lupin GmbH, Switzerland at a total cost of ₹ 93.5 million (previous year ₹ 1.3 million for 100% equity stake) including capital contribution of ₹ 93.5 million (previous year ₹ nil).

c) During the previous year, Lupin Inc., USA (LINC) wholly owned subsidiary of LAHSA subscribed to equity stake of Company's wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA (LPI) at a total cost of ₹ 71.9 million resulting into LINC holding 80% and the Company holding 20% of LPI's equity stake. During the year, LINC has further subscribed to additional equity stake of LPI at a total cost of ₹ 538.5 million resulting into LINC holding 97% and the Company holding 3% of LPI's equity stake.

d) During the year, the Company, through its wholly owned subsidiary Lupin Holdings B.V., Netherlands (LHBV), acquired / subscribed to the equity stake of the following subsidiaries:

i) Additional investment in Lupin Farmaceutica do Brasil LTDA, Brazil (formerly Farma World Importacao e Exportacao de Medicamentos LTDA – EPP) at a total cost of ₹ 51.7 million (previous year ₹ 29.8 million for 100% equity stake).

ii) Additional investment in Generic Health Pty Ltd., Australia at a total cost of ₹ 144.5 million (previous year ₹ nil) thereby making it 100% (previous year 91.04%) subsidiary of LHBV.

iii) Additional investment in Generic Health SDN. BHD., Malaysia at a total cost of ₹ 1.4 million (previous year ₹ 2.2 million).

iv) Acquired balance 40% shareholding of Pharma Dynamics (Proprietary) Ltd., South Africa (PD) consequent to exercise of Put Option by the minority shareholders of PD, for a consideration of ₹ 5977.6 million included under note 10 'Other Current Liabilities'. Accordingly PD has become wholly owned subsidiary of LHBV. Pending the completion of certain formalities as at the year end, the transfer of share certificates in the name of LHBV for the said balance shareholding is in process.

v) Additional investment in Lupin Philippines Inc., Philippines at a total cost of ₹ nil (previous year ₹ 10.9 million).

vi) Additional investment in Hormosan Pharma GmbH, Germany at a total cost of ₹ nil (previous year ₹ 237.6 million).

vii) Additional investment in Lupin Mexico S.A. de C.V., Mexico at a total cost of ₹ nil (previous year ₹ 32.8 million).

viii) Additional investment in Lupin Pharma Canada Limited, Canada at a total cost of ₹ nil (previous year ₹ 30.2 million).

e) During the year, the Company, through Kyowa Pharmaceutical Industry Co., Limited, Japan, wholly owned subsidiary of LHBV subscribed to additional investment in Kyowa CritiCare Co., Limited, Japan (formerly I'rom Pharmaceutical Co., Limited) at a total cost of ₹ 835.8 million (previous year ₹ nil).

The above acquisitions / subscriptions are based on the net asset values, the future projected revenues, operating profits, cash flows and independent valuation reports; as applicable, of the investee companies.

f) Goodwill on Consolidation comprises of:

Particulars	2014-2015	2013-2014
	₹ in million	₹ in million
Opening Balance	6578.7	5073.2
Add: On acquisition / increase of stake in subsidiaries during the year	10762.8	844.3
(Less) / Add : Exchange difference during the year on translation of Goodwill of foreign subsidiaries	(860.4)	661.2
Total	16481.1	6578.7

44. a) The Company holds 100% equity stake at a cost of ₹ 20.0 million in Lupin (Europe) Limited, UK (LEL). The said subsidiary has incurred losses during the year and has negative net worth as at the end of the year. Considering the financial, technical and operational support from the Company and LEL's projections / plans for introducing new products (including products from the Company) in the UK Market in the near future, growth in the turnover and profitability is expected, which would result in improvement in net worth, over a period of time.

b) The Company through its wholly owned subsidiary at Netherlands, namely Lupin Holdings B.V., Netherlands ("LHBV"), holds 100% equity stake at a cost of ₹ 1207.7 million (previous year ₹ 1207.7 million) including capital contribution in Hormosan Pharma GmbH, Germany (Hormosan). Hormosan has incurred losses in the current year and its net worth is negative. Considering the financial, technical and operational support from the Company and Hormosan's projections / plans for introducing new products (including products from the Company) in the German Market in the near future, the Company is of the view that this would lead to an improvement in growth, turnover and profitability, which would result in improvement in net worth, over a period of time.

c) The Company through LHBV has made long-term strategic investments aggregating to ₹ 155.6 million (previous year ₹ 155.6 million) in Lupin Pharma Canada Ltd. (LPCL), wholly owned subsidiary. LPCL has incurred losses in the current year and its net worth is negative as at the end of the year. The Company considers its investments in LPCL to be long term and strategic in nature. LPCL renders marketing services in terms of the marketing and service agreement with the Company for registration and sale of products in Canada. Also based on projections / plans for introducing new products (including products from the Company and Lupin Atlantis Holdings SA) in the Canadian market in near future, the Company is of the view that this would lead to an improvement in growth, turnover and profitability, which would result in improvement in net worth of LPCL over a period of time.

d) Further, networth of Lupin Australia Pty Limited, Pharma Dynamics (Proprietary) Limited, Lupin Atlantis Holdings SA, Lupin Mexico S.A. de C.V., Lupin Philippines Inc., Lupin Healthcare Limited, Generic Health SDN. BHD., Kyowa CritiCare Co., Limited (formerly I'rom Pharmaceutical Co., Limited), Lupin Middle East FZ-LLC, Lupin Farmaceutica do Brasil LTDA (formerly Farma World Importacao e Exportacao De Medicamentos LTDA - EPP), Nanomi B.V., and Laboratorios Grin S.A. de C.V., is substantially less than the carrying amount of investments made by the Company directly or through its subsidiaries.

The Company considers its investments in subsidiaries as strategic and long-term in nature and accordingly, in view of the management, any decline in the value of such long-term investments in subsidiaries is considered to be temporary in nature and hence no provision for diminution in value of investments is considered necessary.

45. Minority Interest represents the minority's share in equity of the subsidiaries as below:

Particulars	As on 31.03.2015 ₹ in million	As on 31.03.2014 ₹ in million
Pharma Dynamics (Proprietary) Limited, South Africa		
-Share in Equity Capital	-	0.2
-Share in Reserves and Surplus	-	473.8
	-	474.0
Multicare Pharmaceuticals Philippines Inc., Philippines		
-Share in Equity Capital	13.2	13.2
-Share in Reserves and Surplus	227.8	156.0
	241.0	169.2
Generic Health Pty Limited, Australia		
-Share in Equity Capital	-	120.4
-Share in Reserves and Surplus	-	(94.2)
	-	26.2
Total	241.0	669.4

46. Auditors' Remuneration:

Particulars	2014-2015	2013-2014
	₹ in million	₹ in million
Payment to Auditors:		
a) As Auditors	43.8	43.5
b) For audit of subsidiaries*	4.3	-
c) for other services including Taxation matters and certifications**	19.6	17.2
d) Reimbursement of out-of-pocket expenses	1.7	0.6
Total	69.4	61.3

* Represents fees in respect of audit of subsidiaries for consolidation requirements of the Company in terms of Section 129(3) of the 2013 Act pursuant to enactment of the 2013 Act.

** Previous year - includes payment for taxation matters to an affiliated firm covered by a networking arrangement which is registered with the Institute of Chartered Accountants of India.

47. a) Foreign Currency Translation Reserve (Refer note 3) represents the net exchange difference on translation of net investment in non-integral foreign operations located at Japan, Australia, Germany, South Africa, Philippines, Mexico, Switzerland and Netherlands from their local currency to the Indian currency. Consequently, in accordance with the Accounting Standard 11 (AS-11) "The Effects of Changes in Foreign Exchange Rates (Revised 2003)", the exchange rate difference on translation of ₹ 1121.0 million (previous year ₹ 829.1 million credited) is debited during the year to such reserve instead of to the Consolidated Statement of Profit and Loss.

    b) LPCL has planned to introduce products of the Company and has commenced rendering of the marketing services to the Company in the Canadian market. Based on its methods of operations, financing models and relationship and support to / from the company, had re-classified its operations w.e.f. the previous financial year as 'integral operations', which were hitherto classified as 'non - integral operations'. Accordingly, the Company had applied the translation procedures in accordance with the Accounting Standard 11 (AS-11) 'The Effects of Changes in Foreign Exchange Rates (Revised 2003)' applicable for integral foreign operations and the resulting net exchange difference is charged / credited to the Consolidated Statement of Profit and Loss instead of accumulating the same in Foreign Currency Translation Reserve. Consequently, the net profit after tax for the year is lower by ₹ 3.4 million (previous year ₹ 2.3 million). There is no impact on shareholders' funds for current as well as previous year.

48. During the year ended March 31, 2010, a wholly owned subsidiary company located in Switzerland, Lupin Atlantis Holdings SA ('LAHSA'), acquired certain assets (Manufacturing Knowhow / Product Marketing Rights, etc.) related to a product, in accordance with the terms of agreement entered into by the said subsidiary. Further, LPCL was in the process of setting up of plant and equipment related to the said product.

    During the year ended March 31, 2012, the aforesaid two subsidiaries, had initiated trial run batches to test whether the product output is as per the desired specifications. During such trial runs, there were some technical issues that were faced for which these Companies were working on resolving the same.

    During the year ended March 31, 2013, based on notice of termination from its toll manufacturing set-up vendor, LPCL had impaired its plant and equipment included in Capital Work-In-Progress amounting to ₹ 128.6 million.

    During the previous year, due to generic launches, the management has decided not to pursue further development of the product and the said Intangible Assets under Development aggregating ₹ 416.0 million have been impaired as stated under note 29 "Other Expenses". The Company is pursuing alternate use of plant and equipment at various sites / with other companies.

49. Excise duty (Refer note 29) includes ₹ 32.9 million (previous year ₹ 34.2 million) being net impact of the excise duty provision on opening and closing stock.

50. The current tax in respect of foreign subsidiaries has been computed considering the applicable tax laws and tax rates of the respective countries, as certified by the local tax consultants / local management of the said subsidiaries.

51. As per best estimate of the management, provision has been made towards probable non-saleable return of goods from customers, as per Accounting Standard 29 (AS-29) notified under Companies (Accounting Standards) Rules, 2006.

Particulars	2014-2015	2013-2014
	₹ in million	₹ in million
Carrying amount at the beginning of the year	672.2	721.7
Add : Additional Provisions made during the year	2083.8	2103.0
Less : Amounts used / utilised during the year	2367.3	2220.7
Add : Exchange Difference during the year	17.7	68.2
Carrying amount at the end of the year	406.4	672.2

52. The aggregate amount of expenditure incurred during the year on Corporate Social Responsibility and shown in the respective heads of account is ₹ 125.8 million.

Particulars	2014-2015
	₹ in million
Donations (Refer note 29)	119.8
Employee Benefits Expense (Refer note 27)	6.0
Total	125.8

53. During the year, pursuant to the notification of Schedule II to the Companies Act, 2013 read together with Accounting Standard 6 (AS - 6) "Depreciation Accounting", the management of the Company has, based on independent technical evaluation, reassessed the remaining useful lives of fixed assets to align with those specified in schedule II and undertaken the componentization of major items of fixed assets with effect from April 1, 2014. In terms of these evaluations, changes has been made in the useful lives of certain assets from their previous estimates as under:

Asset	Previous useful life	Revised Useful Life
Plant and Equipment	9.7 to 21.1 years	10 to 15 years
Furniture and Fixtures	15.8 years	10 years
Vehicles	10.5 years	8 years
Office Equipment	6.2 to 21.1 years	3 to 6 years

Pursuant to the transition provisions prescribed in Schedule II to the Companies Act, 2013, the Company has fully depreciated the carrying value of assets, net of residual value, where the remaining useful life of the asset was determined to be nil as on April 1, 2014, and has adjusted an amount of ₹ 610.8 million (net of deferred tax of ₹ 314.6 million) against the opening Surplus balance in the Consolidated Statement of Profit and Loss under Reserves and Surplus.

The depreciation expense in the Consolidated Statement of Profit and Loss for the year is higher by ₹ 1,618.2 million consequent to the change in the useful life of the assets.

54. During the year, LPI has revised the useful life of certain assets, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers warranties and maintenance support, etc. In terms of these evaluations, changes has been made in the useful lives of certain assets from their previous estimates as under:

Assets class	Previous Useful Life	Revised Useful Life
Computers	3 years	2 - 3 years
Office Equipment	7 years	2- 6 years

The depreciation expense in the Consolidated Statement of Profit and Loss for the year is higher by ₹ 3.4 million consequent to the changes in the useful life of the assets

55. No borrowing cost has been capitalised during the year.

56. Additional information as required by Paragraph 2 of the General Instructions for Preparation of Consolidated Financial Statements to Schedule III to the Companies Act, 2013.

Particulars	Net assets, i.e., total assets minus total liabilities		Share of profit	
	As % of consolidated net assets	₹ in million	As % of consolidated profit	₹ in million
Parent				
Lupin Ltd.	101.73	90,277.4	99.75	23,973.5
Indian Subsidiary				
Lupin Healthcare Ltd., India	0.09	78.8	-	0.4
Foreign Subsidiaries				
Lupin Pharmaceuticals, Inc., USA	1.32	1,172.7	2.73	655.7
Kyowa Pharmaceutical Industry Co., Ltd., Japan	7.51	6,664.6	3.78	909.0
Kyowa CritiCare Co., Ltd., Japan	1.93	1,710.8	0.22	53.1
Hormosan Pharma GmbH, Germany	(0.18)	(155.6)	(0.98)	(236.7)
Pharma Dynamics (Proprietary) Ltd., South Africa	1.50	1,330.7	3.37	810.8
Lupin Australia Pty Ltd., Australia	0.02	21.4	(0.02)	(4.9)
Lupin Holdings B.V., Netherlands	10.99	9,752.3	1.51	363.7
Lupin Atlantis Holdings SA, Switzerland	7.07	6,274.9	(12.59)	(3,027.4)
Multicare Pharmaceuticals Philippines Inc., Philippines	0.55	491.3	0.76	182.9
Lupin (Europe) Ltd.,U.K.	(0.16)	(140.5)	(0.05)	(13.1)
Lupin Pharma Canada Ltd., Canada	(0.04)	(34.6)	(0.29)	(69.5)
Generic Health Pty Ltd., Australia	0.15	125.7	(0.84)	(203.7)
Bellwether Pharma Pty Ltd., Australia	(0.01)	(8.4)	-	-
Max Pharma Pty Ltd., Australia (upto 17 December 2014)	-	-	(0.02)	(5.7)
Lupin Mexico S.A. de C.V., Mexico	0.01	11.1	(0.05)	(12.0)
Lupin Philippines Inc., Philippines	0.05	45.4	0.01	3.5
Generic Health SDN. BHD., Malaysia	-	0.5	-	(0.9)
Lupin Middle East FZ - LLC, UAE	0.01	7.8	(0.05)	(11.2)
Lupin GmbH, Switzerland	0.11	97.6	0.01	2.8
Lupin Inc., USA	1.97	1,746.9	4.84	1,164.0
Lupin Farmaceutica do Brasil LTDA, Brazil	(0.02)	(14.5)	(0.25)	(60.5)
Nanomi B.V., Netherlands	(0.21)	(188.8)	(0.86)	(205.9)
Laboratorios Grin, S.A. de C.V., Mexico (from 30 September 2014)	1.11	987.1	0.42	101.2
Minority Interests in the Subsidiaries				
Multicare Pharmaceuticals Philippines Inc., Philippines	(0.27)	(241.0)	(0.37)	(89.6)
Pharma Dynamics (Proprietary) Ltd., South Africa	-	-	(1.34)	(324.3)
Generic Health Pty Ltd., Australia	-	-	0.01	2.0
Foreign Joint Controlled Entity (as per proportionate consolidation)				
YL Biologics Limited, Japan (from 23 April 2014)	0.04	33.1	0.04	10.1
Total Eliminations / Consolidation Adjustments	(35.27)	(31,306.1)	0.26	65.1
Total	100.00	88,740.6	100.00	24,032.4

The above amounts / percentage of net assets and net profit or (loss) in respect of Lupin Limited and its subsidiaries and Joint Venture are determined based on the amounts of the respective entities included in consolidated financial statements before inter-company eliminations / consolidation adjustments.

57. Related Party Disclosures, as required by Accounting Standard 18 (AS-18) are given below :

A. **Relationships -**

Category I: Jointly Controlled Entity:

YL Biologics Ltd., Japan (from 23 April 2014)

Category II: Key Management Personnel (KMP):

Dr. D. B. Gupta	Chairman
Dr. Kamal K. Sharma	Vice Chairman
Ms. Vinita Gupta	Chief Executive Officer
Mr. Nilesh Gupta	Managing Director
Mrs. M. D. Gupta	Executive Director

Category III: Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)

Dr. Anuja Gupta (Daughter of Chairman)
Mrs. Kavita Sabharwal (Daughter of Chairman)
Dr. Richa Gupta (Daughter of Chairman)
Mrs. Pushpa Khandelwal (Sister of Chairman)
Mrs. Shefali Nath (Wife of Managing Director)
Ms. Veda Nilesh Gupta (Daughter of Managing Director)
Bharat Steel Fabrication and Engineering Works
D. B. Gupta (HUF)
Lupin Human Welfare and Research Foundation
Lupin International Pvt. Limited
Lupin Investments Pvt. Limited
Lupin Holdings Pvt. Limited
Matashree Gomati Devi Jana Seva Nidhi
Novamed Investments Pvt. Limited
Polynova Industries Limited
Rahas Investments Pvt. Limited
Synchem Investments Pvt. Limited
Visiomed Investments Pvt. Limited
Zyma Laboratories Limited
Concept Pharmaceuticals Limited
Shuban Prints

B. Transactions with the related parties:

(₹ in million)

Sr. No.	Transactions	Jointly Controlled Entity*	Key Management Personnel	Others	Total
1.	Rent Expenses	-	-	84.8	84.8
		(-)	(-)	(90.9)	(90.9)
2.	Expenses Recovered / Rent Received	43.0	-	2.7	45.7
		(-)	(-)	(3.0)	(3.0)
3.	Remuneration Paid	-	877.8	-	877.8
		(-)	(707.9)	(-)	(707.9)
4.	Purchases of Goods / Materials	-	-	119.6	119.6
		(-)	(-)	(128.1)	(128.1)
5.	Donations Paid	-	-	143.8	143.8
		(-)	(-)	(135.9)	(135.9)
6.	Dividend Paid	-	19.6	611.1	630.7
		(-)	(46.6)	(1,424.6)	(1,471.2)
7.	License Fees Received	122.3	-	-	122.3
		(-)	(-)	(-)	(-)
8.	Deposits paid for Leave and Licence arrangement for premises	-	-	-	-
		(-)	(-)	(0.4)	(0.4)
9.	Refund of Deposits paid for Leave and Licence arrangement for premises	-	-	-	-
		(-)	(-)	(7.9)	(7.9)
10.	Deposits received for Leave and Licence arrangement for premises	-	-	-	-
		(-)	(-)	(0.1)	(0.1)

Out of the above items transactions in excess of 10% of the total related party transactions are as under :

(₹ in million)

Sr. No.	Transactions	Related party relation	**For the year ended 31.03.2015**	For the year ended 31.03.2014
1.	Rent Expenses			
	Lupin Investments Pvt. Limited	Others	65.9	72.2
	Bharat Steel Fabrication and Engineering Works	Others	10.4	10.3
2.	Expenses Recovered / Rent Received			
	YL Biologics Ltd	Jointly Controlled Entity	43.0	-
	Polynova Industries Limited	Others	2.7	3.0
3.	Remuneration Paid			
	Dr. D. B. Gupta	Key Management Personnel	375.8	371.5
	Dr. Kamal K. Sharma	Key Management Personnel	166.1	134.7
	Ms. Vinita Gupta	Key Management Personnel	248.6	135.8
4.	Purchases of Goods / Materials			
	Concept Pharmaceuticals Limited	Others	93.9	107.2
	Shuban Prints	Others	25.7	20.9
5.	Donations Paid			
	Lupin Human Welfare and Research Foundation	Others	133.8	129.2
6.	Dividend Paid			
	Lupin Holdings Pvt. Limited	Others	121.2	282.8
	Rahas Investments Pvt. Limited	Others	137.1	319.9
	Visiomed Investments Pvt. Limited	Others	130.5	304.6
	Zyma Laboratories Limited	Others	164.9	384.7
7.	License Fees Received			
	YL Biologics Ltd	Jointly Controlled Entity	122.3	-
8.	Deposits paid for Leave and Licence arrangement for premises			
	Bharat Steel Fabrication and Engineering Works	Others	-	0.4
9.	Refund of Deposits paid for Leave and Licence arrangement for premises			
	Lupin Investments Pvt. Limited	Others	-	7.9
10.	Deposits received for Leave and Licence arrangement for premises			
	Polynova Industries Limited	Others	-	0.1

C. **Balances due from / to the related parties:**

(₹ in million)

Sr. No.	Transactions	Jointly Controlled Entity*	Key Management Personnel	Others	Total
1.	Deposits paid under Leave and Licence arrangement for premises	-	-	54.7	54.7
		(-)	(-)	(54.7)	(54.7)
2.	Trade Payables	-	-	3.4	3.4
		(-)	(58.9)	(6.6)	(65.5)
3.	Advances to Vendors	149.1	-	-	149.1
		(-)	(-)	(-)	(-)
4.	Commission Payable	-	326.8	-	326.8
		(-)	(328.5)	(-)	(328.5)
5.	Expenses Receivable	-	-	-	-
		(-)	(-)	(0.1)	(0.1)
6.	Deposits received under Leave and Licence arrangement for premises	-	-	0.1	0.1
		(-)	(-)	(0.1)	(0.1)

* Transactions with Jointly Controlled Entity has been reported at full value

i) Figures in brackets are for previous year.

ii) Related party relationship is as identified by the Company and relied upon by the Auditors.

58. The Consolidated Financial Statements includes results of operations of one new subsidiary acquired, proportionate share of income and expenditure of one Jointly controlled entity incorporated, results of operations of one subsidiary liquidated during the year and results of operations of the entire twelve months of four subsidiaries incorporated / acquired during the previous year. Accordingly, the current year figures are not strictly comparable with those of the previous year.

59. Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

Signatures to note 1 to 59

For **Lupin Limited**

Dr. Desh Bandhu Gupta
Chairman
DIN: 00209378

Dr. Kamal K. Sharma
Vice Chairman
DIN: 00209430

Vinita Gupta
Chief Executive Officer
DIN: 00058631

Nilesh Gupta
Managing Director
DIN: 01734642

M. D. Gupta
Executive Director
DIN: 00209461

Dr. Vijay Kelkar
Director
DIN: 00011991

Richard Zahn
Director
DIN: 02937226

R. A. Shah
Director
DIN: 00009851

Dr. K. U. Mada
Director
DIN: 00011395

Dileep C. Choksi
Director
DIN: 00016322

Ramesh Swaminathan
Chief Financial Officer

R. V. Satam
Company Secretary
ACS - 11973

Place : Mumbai
Dated : May 13, 2015

STANDALONE ACCOUNTS

INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF LUPIN LIMITED

Report on the Standalone Financial Statements

We have audited the accompanying standalone financial statements of LUPIN LIMITED ("the Company"), which comprise the Balance Sheet as at March 31, 2015, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2015, and its profit and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2015 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

   (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

   (e) On the basis of the written representations received from the directors as on March 31, 2015 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2015 from being appointed as a director in terms of Section 164(2) of the Act.

   (f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

      i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements - Refer Note 30 (a), (b), (c) and (g) to the financial statements;

      ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts - Refer Notes 42(i) and 43 to the financial statements;

      iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

K.A. Katki
Partner
(Membership No.: 038568)

Place : Mumbai
Dated : May 13, 2015

ANNEXURE TO
THE INDEPENDENT AUDITORS' REPORT

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) In respect of its fixed assets:

(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

(b) The Company has a program of verification of fixed assets to cover all the items in a phased manner over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain fixed assets were physically verified by the Management during the year. According to the information and explanations given to us no material discrepancies were noticed on such verification.

(ii) In respect of its inventories:

(a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals.

(b) In our opinion and according to the information and explanations given to us, the procedures of physical verification of inventories followed by the Management were reasonable and adequate in relation to the size of the Company and the nature of its business.

(c) In our opinion and according to the information and explanations given to us, the Company has maintained proper records of its inventories and no material discrepancies were noticed on physical verification.

(iii) The Company has not granted any loans, secured or unsecured, to companies, firms or other parties covered in the Register maintained under Section 189 of the Companies Act, 2013.

(iv) In our opinion and according to the information and explanations given to us, having regard to the explanations that some of the items purchased are of special nature and suitable alternative sources are not readily available for obtaining comparable quotations, there is an adequate internal control system commensurate with the size of the Company and the nature of its business with regard to purchases of inventory and fixed assets and the sale of goods and services. During the course of our audit, we have not observed any major weakness in such internal control system.

(v) According to the information and explanations given to us, the Company has not accepted any deposit during the year in terms of provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013. There were no unclaimed deposits as at the year end.

(vi) We have broadly reviewed the cost records maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013, and are of the opinion that, *prima facie*, the prescribed cost records have been made and maintained. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

(vii) According to the information and explanations given to us, in respect of statutory dues:

(a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities.

(b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2015 for a period of more than six months from the date they became payable.

(c) Details of dues of Income-tax, Sales Tax, Service Tax and Excise Duty which have not been deposited as on March 31, 2015 on account of disputes are given below:

Name of Statute	Nature of Dues	Forum where Dispute is Pending	Period to which the Amount Relates	Amount Involved (₹ In million)
Income-tax Act, 1961	Income tax	Commissioner of Income-tax (Appeals) – LTU	2006-2008	55.5
Central Excise Act, 1944	Excise duty	Customs, Excise and Service Tax Appellate Tribunal (CESTAT)	1996-1997, 1998-2000, 2001-2010	48.6
		Commissioner of Central Excise (Appeals)	1997-1998 2002-2007	1.1
	Service tax credit matters	Customs, Excise and Service Tax Appellate Tribunal (CESTAT)	2005-2008	202.3
Central and various States' Sales Tax Acts	Sales tax	Sales Tax Tribunal	2006-2009	21.0
		Commissioner of Sales Tax (Appeals)	2004-2005, 2006-2007, 2008-2014	25.0
		Assistant Commissioner of Sales Tax (Investigations)	2006-2011	20.7
		Additional Commissioner	2002-2003, 2011-2013	4.8
		Deputy Commissioner	2000-2001	0.3

There are no dues of Wealth Tax, Customs Duty, Value Added Tax and Cess which have not been deposited as on March 31, 2015 on account of disputes.

(d) The Company has been regular in transferring amounts to the Investor Education and Protection Fund in accordance with the relevant provisions of the Companies Act, 1956 (1 of 1956) and Rules made thereunder within time.

(viii) The Company does not have accumulated losses at the end of the financial year and the Company has not incurred cash losses during the financial year covered by our audit and in the immediately preceding financial year.

(ix) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not obtained loans from financial institutions or by way of debentures.

(x) In our opinion and according to the information and explanations given to us, the terms and conditions of the guarantees given by the Company for loans taken by others from banks and financial institutions are not, *prima facie*, prejudicial to the interests of the Company.

(xi) In our opinion and according to the information and explanations given to us, the term loans have been applied by the Company during the year for the purposes for which they were obtained, other than temporary deployment pending application.

(xii) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

K.A. Katki
Partner
(Membership No.: 038568)

Place : Mumbai
Dated : May 13, 2015

BALANCE SHEET AS AT MARCH 31, 2015

	Note	As at 31.03.2015 ₹ in million	As at 31.03.2014 ₹ in million
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	2	899.0	896.8
Reserves and Surplus	3	89,378.4	68,893.6
		90,277.4	69,790.4
Non-Current Liabilities			
Long-Term Borrowings	4	191.4	242.4
Deferred Tax Liabilities (net)	5	1,892.2	2,479.3
Other Long-Term Liabilities	6	85.0	95.1
Long-Term Provisions	7	1,031.2	769.2
		3,199.8	3,586.0
Current Liabilities			
Short-Term Borrowings	8	209.5	1,151.6
Trade Payables	9	10,420.4	9,838.5
Other Current Liabilities	10	1,014.8	1,265.1
Short-Term Provisions	11	4,955.2	2,358.0
		16,599.9	14,613.2
	TOTAL	110,077.1	87,989.6
ASSETS			
Non-Current Assets			
Fixed Assets	12		
Tangible Assets		20,206.7	21,709.1
Intangible Assets - Acquired		149.3	85.5
Capital Work-in-Progress		4,899.6	2,670.5
		25,255.6	24,465.1
Non-Current Investments	13	17,902.6	9,890.5
Long-Term Loans and Advances	14	2,394.5	3,197.0
Other Non-Current Assets	15	3.2	-
		45,555.9	37,552.6
Current Assets			
Current Investments	16	16,539.7	1,746.1
Inventories	17	17,395.1	13,722.4
Trade Receivables	18	25,152.1	28,599.2
Cash and Cash Equivalents	19	593.0	1,462.8
Short-Term Loans and Advances	20	2,925.0	2,594.4
Other Current Assets	21	1,916.3	2,312.1
		64,521.2	50,437.0
	TOTAL	110,077.1	87,989.6

See accompanying notes forming part of the financial statements

In terms of our report attached
For **Deloitte Haskins & Sells LLP**
Chartered Accountants

K.A. Katki
Partner

For **Lupin Limited**

Dr. Desh Bandhu Gupta
Chairman
DIN: 00209378

Dr. Kamal K. Sharma
Vice Chairman
DIN: 00209430

Vinita Gupta
Chief Executive Officer
DIN: 00058631

Nilesh Gupta
Managing Director
DIN: 01734642

M. D. Gupta
Executive Director
DIN: 00209461

Dr. Vijay Kelkar
Director
DIN: 00011991

Richard Zahn
Director
DIN: 02937226

R. A. Shah
Director
DIN: 00009851

Dr. K. U. Mada
Director
DIN: 00011395

Dileep C. Choksi
Director
DIN: 00016322

Ramesh Swaminathan
Chief Financial Officer

R. V. Satam
Company Secretary
ACS - 11973

Place : Mumbai
Dated : May 13, 2015